Phase 3 HOPE-3 Clinical Trial Results for Deramiocel in Duchenne Muscular Dystrophy Published in The Lancet

Capricor Therapeutics announced that The Lancet, a peer-reviewed medical journal, has published the final one-year results from its pivotal Phase 3 HOPE-3 clinical trial. The trial evaluated deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD), demonstrating a significant slowing of upper limb function decline and clinically meaningful cardiac benefits in patients with advanced disease.